Biopharmaceutical Companies Acknowledge GenOway as Their Preferred Provider for Genetically Modified Rodents.LYON, France -- 2007: 5 corporate deals with US-based and European companies It may never be fully completed or, depending on its its nature, it may be that it can never be completed. However, new and revised entries in the list are always welcome. This is a list of companies from the countries in the European Union. 2008: corporate deal with Boehringer Ingelheim Pharmaceuticals Inc (USA). 2008: corporate deal with Eisai Co., Ltd (Japan) 2008: extension of the 2007 2 million USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. deal with biopharmaceutical firm (USA) 2008: extension of the 2007 1.7 million USD deal with NGFN NGFN Nationale Genomforschungsnetz (German: Genome Analysis Network) (Germany) genOway (Paris:ALGEN ALGEN Automatic Load Generator ), the biotechnology company dedicated to the development of genetically modified genetically modified Adjective (of an organism) having DNA which has been altered for the purpose of improvement or correction of defects genetically modified genetic adj [food etc] → rodent models, reports recent 2008 business achievements demonstrating that the company is viewed as the preferred provider by leading biopharmaceutical companies. "Our strategy is the one required by biopharmaceutical companies: our exhaustive technology platform enables us to develop the right geneticaly modified mouse and rat models for each project and, our production capacity is routinely handling corporate deals of several tens of models ", said Kader Thiam, VP Transgenic Technologies for genOway In 2007, genOway announced the signing of 5 corporate deals, including a multi-million dollar master services agreement with a leading US-based biopharmaceutical firm, as well as its commitment to the German-National-Genome-Research-Network (NGFN) with a 1.7 million USD agreement. genOway announced today that both agreements have already been increased to include the development of additional models and services, demonstrating that the services offered to researchers match their requirements and underlining the quality of the technologies genOway has developed. Recently, the company announced two master services agreements with Boehringer Ingelheim Pharmaceuticals Inc. and with the Japanese pharmaceutical leader Eisai Co., Ltd. Today, 23 biopharmaceutical companies have corporate agreement with genOway to develop genetically modified mouse and rat models, either for their target validation programs, for the development of in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. screening tools or DMPK DMPK Drug Metabolism and Pharmacokinetics DMPK Dystrophia Myotonica Protein Kinase & toxicological studies. Additional agreements should be announced in the coming months. About genOway: www.genoway.com genOway (ALTERNEXT-NYSE:ALGEN) is a biotechnology company dedicated to the development of genetically modified mouse and rat models aimed at enhancing the relevancy of in vivo studies. genOway's expertise comprises transgenic technologies such as knock-out, knock-in, knock-down, point-mutation, humanization Humanization Fusing the constant and variable framework region of one or more human immunoglobulins with the binding region of an animal immunoglobulin, done to reduce human reaction against the fusion antibody. Mentioned in: Alemtuzumab , and innovative patented technologies adapted to target validation, in vivo drug screening, etc.. Collaborations with world leaders (Charles River Laboratories, Invitrogen, Tet systems) enable genOway to provide its customer with a complete portfolio of products and services. genOway will attend BIO2008 in San Diego. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion